**Supplemental Table A1. Trials of first-line pemetrexed plus carboplatin included in the meta-analysis.**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **CT.gov Identifier** | **Trial Alias** | **P+Cb *N* in Meta-analysis** | **Cb AUC  (mg/min🞄mL)** | **Pa+Cbb First-Line Therapyc** |
| **NCT00520676** | H3E-CR-S380d | 105 | 5 | 6 cycles |
| **NCT01020786** | H3E-JE-JMIIe | 109 | 6 | 4 cycles + P MTC |
| **NCT00402051** | H3E-SB-S109f | 52 | 6 | 6 cycles |
| **NCT00948675** | PRONOUNCEg | 171 | 6 | 4 cycles + P MTC |
| **NCT00308750** | H6Q-US-S004h | 49 | 6 | 6 cycles |

AUC: area under the concentration-time curve; Cb: carboplatin; CT.gov: ClinicalTrials.gov; MTC: maintenance; P: pemetrexed.

aPemetrexed 500 mg/m2 IV, plus folic acid and vitamin B12 supplementation.

bCb administered at a dose corresponding to the target area under the concentration-time curve.

c21-day cycles.

dRodrigues-Pereira J, et al. 20119.

eOkamoto I, et al. 201310.

fSchuette WH, et al. 201311.

gZinner RG, et al. 201512.

hSocinski MA, et al. 201013.